Place of diclofenac in therapeutic standards in rheumatology

2021 ◽  
Vol 14 (3) ◽  
pp. 274-278
Author(s):  
Robert Rupiński ◽  
Jarosław Woroń
Keyword(s):  
Side Effects ◽  
Autoimmune Diseases ◽  
Clinical Experience ◽  
Inflammatory Pain ◽  
Individual Characteristics ◽  
Drug Selection ◽  
Inflammatory Drug ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
The Individual

Non-steroidal anti-inflammatory drugs (NSAIDs) are drugs that are difficult to replace in the treatment of inflammatory pain. Both the mechanisms involved in the development of inflammatory pain and the individual characteristics of each non-steroidal anti-inflammatory drugs currently allow for personalized drug selection in such a way as to escalate its effectiveness while minimizing the risk of side effects. Diclofenac is a non-steroidal anti-inflammatory drug with one of the longest clinical experience. Since the beginning of the 70s of the last century, it has become an important element of everyday rheumatological practice, used in both degenerative and autoimmune diseases.

Reducing pain in certain forms of obstetric pathology: nonsteroidal anti-inflammatory drugs (Сlinical lecture)

2017 ◽  
pp. 9-14
Author(s):  
L. Nazarenko ◽  
Keyword(s):  
Preterm Birth ◽  
Side Effects ◽  
Key Words ◽  
Clinical Efficacy ◽  
Premature Birth ◽  
Pain Syndrome ◽  
Inflammatory Drug ◽  
Threatened Abortion ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The article discusses the pathogenetic basis for the use of non-steroidal anti-inflammatory drugs (NSPVP) in obstetric practice for the treatment of pain syndrome in women with threatened abortion and pathological preliminary period. Provided with modern views on the mechanisms of analgesic clinical efficacy, side effects NSPVP. Provides information about the place of NSPVP during pregnancy, the risks to the fetus, the positive aspects in the conduct of women at risk of preterm birth, the pathological preliminary period. Key words: nonsteroidal anti-inflammatory drug, pain, premature birth, preliminary period.

Potential complications of nonsteroidal anti-inflammatory drug therapy

1989 ◽  
Vol 79 (12) ◽  
pp. 605-614
Author(s):  
GD Corrigan ◽  
L Pantig-Felix ◽  
IO Kanat
Keyword(s):  
Health Care ◽  
Patient Satisfaction ◽  
Drug Therapy ◽  
Side Effects ◽  
Mechanism Of Action ◽  
Drug Class ◽  
Inflammatory Drug ◽  
The Us ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Since indomethacin was first marketed, some 40 years ago, the class of nonsteroidal anti-inflammatory drugs has grown larger than any other drug class in history. At present, there are at least 25 such drugs being used in the US and abroad, both clinically and in research. Despite their widespread use, their implications to health care are just beginning to be understood. The authors review updated theories on the mechanism of action, side effects, and drug interactions of nonsteroidal anti-inflammatory drug therapy. Proposed guidelines for monitoring their use are given. A more thorough understanding of the risks-to-benefits ratio is provided in an effort to achieve maximum patient satisfaction and safety.

scholarly journals The individual characteristics of the patients with nonspecific back pain aff ecting the dynamics of pain syndrome in the treatment with non-steroidal anti-inflammatory drugs

2020 ◽  
pp. 21-25
Author(s):  
Iryna Maslova ◽  
Natalia Mykhailovska ◽  
Oleg Devinyak ◽  
Vladyslav Moseiko ◽  
Tetiana Slobodin
Keyword(s):  
Back Pain ◽  
Interleukin 1 ◽  
Pain Syndrome ◽  
Interleukin 10 ◽  
Individual Characteristics ◽  
Efficacy And Safety ◽  
Analog Scale ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
The Individual

The effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of patients with non-specific back pain is variable, from complete ineffectiveness to the occurrence of side effects. The eff ect of NSAIDs is affected by various factors, including individual characteristics of the patient. The aim of the study was to improve the diagnostic approach to patients with non-specific back pain to identify individual indicators that can affect the efficacy and safety of NSAID therapy. The study involved 139 patients — men and women aged 30 to 60 years — with acute nonspeci fic back pain. All patients took meloxicam or celecoxib for 10 days, then observed during 90 days. On the 1st, 10th, 30th and 90th days the patients were assessed on scales — Visual Analog Scale ( VAS), Beck Depression Inventory. In the 1st and 10th days in 20 patients we determined the levels of interleukin 1 (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10). The patients with arterial hypertension (p = 0,0053), diabetes (p = 0.04), depression (p = 0.01) had significantly worse treatment outcomes. Reduction in the levels of IL-1β and the ratio IL-6/IL-10 led to a significant reduction in pain intensity in patients with back pain. The prescription of NSAIDs for patients with back pain should be assessed from the perspective of the individual patient, including the presence of comorbidity, emotional or genetic markers, and so on, which should increase the efficiency and safety of NSAIDs treatment. Keywords: non-steroidal anti-inflammatory drugs, back pain, CYP2C9 genetic polymorphism, cytokines IL-1, IL-6/IL-10

scholarly journals Non-Steroid Inflammation (Nsaid) Drug Selling Profile Based On Self-Medication Service at Mida Farma I Drugstore Gresik

2021 ◽  
Vol 1 (1) ◽  
pp. 24-29
Author(s):  
Helmi Hanifah ◽  
Pemta Tiadeka ◽  
Riskha Aulia
Keyword(s):  
Side Effects ◽  
Plasma Level ◽  
Data Collection ◽  
Maximum Plasma ◽  
Observational Method ◽  
Self Medication ◽  
Inflammatory Drug ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory

This study aims to determine the profile of self-medication sales of non-steroidal anti-inflammatory drugs at Mida Farma I Drugstore Gresik. It is conducted by using the observational method with data collection and observation on the Non-Steroid Anti-Inflammatory Drug (NSAID) stock cards in February 2020 at Mida Farma I Drugstore Gresik. The results show that the highest sales profile is the non-selective group of 87.68%, then the second is the COX-2 selective group of 12.32%. The most sold drug is ibuprofen of 20% and the lowest sold one is Aspirin of 14%. The pharmacokinetics of ibuprofen are it absorbs very quickly through the stomach; has a maximum plasma level that has reached 1 to 2 hours; and has low side effects

scholarly journals Non-steroidal anti-inflammatory drugs and arterial hypertension: drug interaction-adjusted management of patients

2021 ◽  
pp. 258-264
Author(s):  
K. M. Muratov ◽  
E. V. Shikh ◽  
N. I. Lapidus ◽  
Zh. I. Sizova
Keyword(s):  
Gene Polymorphism ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Genetic Factors ◽  
Antihypertensive Drugs ◽  
Individual Characteristics ◽  
Wide Range ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
The Individual

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most common drugs in clinical practice and account for 5–10% of all drugs prescribed each year. However, the use of this group of drugs is associated with the risk of a wide range of side effects, most of which are cardiovascular complications. In addition, NSAIDs interact with other drugs, for example, their effect on antihypertensive therapy has recently been recognized as particularly important. Improvement of not only efficacy, but also safety is another important principle of rational pharmacotherapy. Adverse drug reactions (ADR) can very often result from underlying genetic factors of the human body. In this regard, a personalized approach suggesting the prescription of drugs according to the individual characteristics of patients is especially important. In such cases, pharmacogenetic testing is the most promising method that identifies the genetic factors of patients and allows to predict patients’ responses to specific drugs. This applies especially to a large range of drugs metabolised via the cytochrome P450 system in the liver. Results from numerous studies show that the effect of P450 family gene polymorphism determines the individual sensitivity to antihypertensive drugs, as it is these isozymes that are involved in the metabolism of drugs used to treat arterial hypertension (AH). In particular, the cytochrome (CYP) 450 isoenzyme is one of the basic enzymes involved in the biotransformation of losartan, an angiotensin receptor antagonist. Therefore, the CYP2C9 gene polymorphism largely determines the pharmacological response to NSAIDs and affects the effectiveness of antihypertensive therapy due to the change in the drug metabolism, as well as the structure and function of the receptors, on which they have an effect.

Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs

2019 ◽  
Vol 25 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Manas A. Rane ◽  
Alexander Gitin ◽  
Benjamin Fiedler ◽  
Lawrence Fiedler ◽  
Charles H. Hennekens
Keyword(s):  
Cardiovascular Disease ◽  
Side Effects ◽  
Health Care Providers ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Care Providers ◽  
Relieve Pain ◽  
Gastrointestinal Side Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin, naproxen, diclofenac, and ibuprofen, as well as selective cyclooxygenase 2 inhibitors such as celecoxib. Their use is common, as well as their side effects which cause 100 000 hospitalizations and 17 000 deaths annually. Recently, the US Food and Drug Administration strengthened its warning about the risks of cardiovascular disease (CVD) attributed to nonaspirin NSAIDs. Methods: When the sample size is large, randomization provides control of confounding not possible to achieve with any observational study. Further, observational studies and, especially, claims data have inherent confounding by indication larger than the small to moderate effects being sought. Results: While trials are necessary, they must be of sufficient size and duration and achieve high compliance and follow-up. Until then, clinicians should remain uncertain about benefits and risks of these drugs. Conclusions: Since the totality of evidence remains incomplete, health-care providers should consider all these aforementioned benefits and risks, both CVD and beyond, in deciding whether and, if so, which, NSAID to prescribe. The factors in the decision of whether and, if so, which NSAID to prescribe for relief of pain from inflammatory arthritis should not be limited to risks of CVD or gastrointestinal side effects but should also include potential benefits including improvements in overall quality of life resulting from decreases in pain or impairment from musculoskeletal pain syndromes. The judicious individual clinical decision-making about the prescription of NSAIDs to relieve pain based on all these considerations has the potential to do much more good than harm.

The role of celecoxib as a potential inhibitor in the treatment of inflammatory diseases - a review

2021 ◽  
Vol 28 ◽  
Author(s):  
Josiane Viana Cruz ◽  
Joaquín María Campos Rosa ◽  
Njogu Mark Kimani ◽  
Silvana Giuliatti ◽  
Cleydson Breno Rodrigues dos Santos
Keyword(s):  
Side Effects ◽  
Inflammatory Diseases ◽  
Structural Basis ◽  
Potential Inhibitor ◽  
Cyclooxygenase 1 ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

: This article presents a simplified view of celecoxib as a potential inhibitor in the treatment of inflammatory diseases. The enzyme cyclooxygenase (COX) has, predominantly, two isoforms called cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2). The former plays a constitutive role that is related to homeostatic effects in renal and platelets, while the latter is mainly responsible for induction of inflammatory effects. Since COX-2 plays an important role in the pathogenesis of inflammatory diseases, it has been signaled as a target for the planning of anti-inflammatory intermediates. Many inhibitors developed and planned for COX-2 inhibition have presented side effects to humans, mainly in the gastrointestinal and/or cardiovascular tract. Therefore, it is necessary to design new potential COX-2 inhibitors, which are relatively safe and without side effects. To this end, of the generation of non-steroidal anti-inflammatory drugs from “coxibs”, celecoxib is the only potent selective COX-2 inhibitor that is still commercially available. Thus, the compound celecoxib became a commercial prototype inhibitor for the development of anti-inflammatory agents for COX-2 enzyme. In this review, we provide highlights where such inhibition should provide a structural basis for the design of promising new non-steroidal anti-inflammatory drugs (NSAIDs) which act as COX-2 inhibitors with lesser side effects on the human body.

Sign in / Sign up

Export Citation Format

Share Document